Pacific Biosciences of California, Inc. (PACB)Healthcare | Medical Devices | Menlo Park, United States | NasdaqGS
1.69 USD
+0.06
(3.681%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.70 +0.01 (0.592%) ⇧ (April 17, 2026, 7:45 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:04 p.m. EDT
PACB is currently in a volatile and uncertain position, with a high beta and negative earnings, indicating significant risk. The recent price movements show a lack of clear momentum, and the stock has been trading below its 52-week low. While there are some positive analyst recommendations, the overall fundamentals and forecast suggest a lack of strong growth potential. The absence of dividends and the high debt-to-equity ratio make it a risky investment for both short-term and long-term investors. The options activity suggests a mixed outlook, with both bullish and bearish signals, but the overall market conditions and company performance indicate caution. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.498058 |
| AutoARIMA | 0.498060 |
| MSTL | 0.504066 |
| AutoTheta | 0.550669 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 2.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.034 |
| Excess Kurtosis | 0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13131.838 |
| Revenue per Share | 0.533 |
| Market Cap | 510,377,152 |
| Forward P/E | -4.06 |
| Beta | 2.33 |
| Website | https://www.pacb.com |
As of April 11, 2026, 3:04 p.m. EDT: Options speculators are showing a mix of sentiment. The calls have significant open interest and volume at strikes above the current price, indicating potential bullish sentiment for higher prices. However, the puts also show activity at lower strikes, suggesting some bearish positioning. The implied volatility (IV) is relatively low, which may indicate a lack of confidence or uncertainty about future price movements. The overall options activity suggests a cautious outlook with potential for both upward and downward movements, depending on the strike prices and expiration dates.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4824561 |
| Address1 | 1,305 O’Brien Drive |
| All Time High | 53.69 |
| All Time Low | 0.85 |
| Ask | 2.13 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 5,449,480 |
| Average Daily Volume3 Month | 6,526,353 |
| Average Volume | 6,526,353 |
| Average Volume10Days | 5,449,480 |
| Beta | 2.332 |
| Bid | 1.26 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 0.018 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.69 |
| Current Ratio | 5.15 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.75 |
| Day Low | 1.66 |
| Debt To Equity | 13,131.838 |
| Display Name | Pacific Biosciences of California |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -169,226,000 |
| Ebitda Margins | -1.0576301 |
| Enterprise To Ebitda | -5.515 |
| Enterprise To Revenue | 5.833 |
| Enterprise Value | 933,293,120 |
| Eps Current Year | -0.50786 |
| Eps Forward | -0.41617 |
| Eps Trailing Twelve Months | -1.82 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 618 2699 |
| Fifty Day Average | 1.5106 |
| Fifty Day Average Change | 0.17940009 |
| Fifty Day Average Change Percent | 0.11876082 |
| Fifty Two Week Change Percent | 48.24561 |
| Fifty Two Week High | 2.73 |
| Fifty Two Week High Change | -1.04 |
| Fifty Two Week High Change Percent | -0.38095236 |
| Fifty Two Week Low | 0.85 |
| Fifty Two Week Low Change | 0.84000003 |
| Fifty Two Week Low Change Percent | 0.9882353 |
| Fifty Two Week Range | 0.85 - 2.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,288,186,200,000 |
| Float Shares | 293,747,699 |
| Forward Eps | -0.41617 |
| Forward P E | -4.0608406 |
| Free Cashflow | 97,545,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 485 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.34280998 |
| Gross Profits | 54,852,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09345999 |
| Held Percent Institutions | 0.59419 |
| Implied Shares Outstanding | 301,998,292 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. |
| Long Name | Pacific Biosciences of California, Inc. |
| Market | us_market |
| Market Cap | 510,377,152 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_11461617 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -546,376,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 510,377,113 |
| Number Of Analyst Opinions | 6 |
| Open | 1.66 |
| Operating Cashflow | -111,209,000 |
| Operating Margins | -1.34537 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 521 8000 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.5917154 |
| Post Market Price | 1.7 |
| Post Market Time | 1,776,469,515 |
| Previous Close | 1.63 |
| Price Eps Current Year | -3.327689 |
| Price Hint | 4 |
| Price To Book | 93.88889 |
| Price To Sales Trailing12 Months | 3.1897576 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.324 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.125 |
| Region | US |
| Regular Market Change | 0.0600001 |
| Regular Market Change Percent | 3.68099 |
| Regular Market Day High | 1.75 |
| Regular Market Day Low | 1.66 |
| Regular Market Day Range | 1.66 - 1.75 |
| Regular Market Open | 1.66 |
| Regular Market Previous Close | 1.63 |
| Regular Market Price | 1.69 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 8,390,043 |
| Return On Assets | -0.33728 |
| Return On Equity | -2.13452 |
| Revenue Growth | 0.138 |
| Revenue Per Share | 0.533 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 301,998,292 |
| Shares Percent Shares Out | 0.1511 |
| Shares Short | 45,631,632 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 38,191,242 |
| Short Name | Pacific Biosciences of Californ |
| Short Percent Of Float | 0.1718 |
| Short Ratio | 7.76 |
| Source Interval | 15 |
| State | CA |
| Symbol | PACB |
| Target High Price | 3.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 3.0 |
| Total Cash | 279,505,984 |
| Total Cash Per Share | 0.926 |
| Total Debt | 702,422,016 |
| Total Revenue | 160,004,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.6757 |
| Two Hundred Day Average Change | 0.014300108 |
| Two Hundred Day Average Change Percent | 0.008533812 |
| Type Disp | Equity |
| Volume | 8,390,043 |
| Website | https://www.pacb.com |
| Zip | 94,025 |